Gypenoside LI
Modify Date: 2025-08-27 19:06:53
Gypenoside LI structure
|
Common Name | Gypenoside LI | ||
|---|---|---|---|---|
| CAS Number | 94987-10-7 | Molecular Weight | 801.01 | |
| Density | 1.33±0.1 g/cm3(Predicted) | Boiling Point | 912.3±65.0 °C(Predicted) | |
| Molecular Formula | C42H72O14 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of Gypenoside LIGypenoside LI, a gypenoside monomer, possesses anti-tumor activity. Gypenoside LI induces cell apoptosis, cell cycle and migration[1][2]. |
| Name | Gypenoside LI |
|---|
| Description | Gypenoside LI, a gypenoside monomer, possesses anti-tumor activity. Gypenoside LI induces cell apoptosis, cell cycle and migration[1][2]. |
|---|---|
| Related Catalog | |
| In Vitro | Gypenoside LI (0-80 μM) inhibits A549 cells in a dose-dependent manner. Gypenoside LI induces G2/M and arrest apoptosis in A549 cells[1]. Gypenoside LI increases intracellular ROS level. Gypenoside LI suppressed migration of A549 cells[1]. Gypenoside LI could obviously suppress the expression of CDK1 protein rather thanCDK2 and CDK4 proteins[1]. Gypenoside LI inhibits cell proliferation and upregulates expression of miR-128-3p in melanoma cells[2]. Gypenoside LI (75 and 29.71 μg/mL) can induce intrinsic apoptosis along with S phase arrest. Gypenoside LI inhibited the colony formation ability of melanoma through inhibition of the Wnt/β-catenin signaling pathway[2]. Gypenoside LI induces PARP cleavage, increased the expression of cleaved caspase-9 and BID death agonist, and downregulates the expression of FLIP (long form) and BCl-2 in the A375 and SK-MEL-28 melanoma cells[2]. Cell Viability Assay[1] Cell Line: A549 cells. Concentration: 0-80 μM. Incubation Time: 24 h. Result: Displayed the strongest activity with the IC50 values of 21.36 ± 0.78 μM. |
| References |
| Density | 1.33±0.1 g/cm3(Predicted) |
|---|---|
| Boiling Point | 912.3±65.0 °C(Predicted) |
| Molecular Formula | C42H72O14 |
| Molecular Weight | 801.01 |